 SEATTLE, Feb. 03, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq:ATOS, a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access or compassionate use single-patient studies of Atossas Endoxifen. 